Emergent BioSolutions vs MannKind
EBS and MNKD side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How EBS and MNKD compare
MannKind is the larger company, worth 4.4 times as much as Emergent BioSolutions ($1.3B against $310M).
MannKind grew revenue faster over the last twelve months (31.7% versus −17.7% for Emergent BioSolutions).
MannKind keeps more of each dollar of sales as profit, with a net margin of −18.1% compared with −40.2% at Emergent BioSolutions.
Emergent BioSolutions scores higher on the StockData Score (7 against 6 for MannKind), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | EBS | MNKD |
|---|---|---|
| Size and price | ||
| Market cap | $310M | $1.3B |
| Share price | $6.04 | $4.19 |
| Change, 1 year | −45.0% | −22.7% |
| Change, 5 years | −84.9% | −11.8% |
| Beta (5Y) | 1.85 | 1.08 |
| Employees | 900 | 241 |
| StockData Score | ||
| Total score | 7 (better) | 6 |
| Valuation score | 3 (better) | 1 |
| Growth score | 0 | 2 (better) |
| Performance score | 2 | 2 |
| Health score | 2 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 0.5× (better) | 3.3× |
| P/B | 1.0× | – |
| EV/EBITDA | – | 88.3× |
| P/FCF | 1.6× | – |
| FCF yield | 60.8% (better) | −5.8% |
| Fair value | $21.23 | $1.11 |
| Margin of safety | 71.5% (better) | −279% |
| Growth | ||
| Revenue growth (TTM) | −17.7% | 31.7% (better) |
| Revenue growth, 5Y average | −14.0% | 39.9% (better) |
| Net income growth (TTM) | −443% | −356% (better) |
| EPS growth (TTM) | −486% | −330% (better) |
| EPS growth, 5Y average | −30.4% | – |
| Profitability | ||
| Gross margin | 48.4% | 88.6% (better) |
| Operating margin | −27.7% | −2.9% (better) |
| Net margin | −40.2% | −18.1% (better) |
| FCF margin | 29.0% (better) | −19.0% |
| Return on equity | −58.2% | – |
| Return on invested capital | −17.3% | – |
| Financial health | ||
| Debt / equity | 1.62 | – |
| Interest coverage | −4.0× | −0.3× (better) |
| Current ratio | 4.58 (better) | 2.22 |
| Altman Z-score | 0.34 (better) | −4.51 |
| Piotroski F-score | 7 (better) | 5 |
| Dividends and buybacks | ||
| Buyback yield | 8.8% | – |
| Shareholder yield | 8.8% (better) | 0.00% |
| Ownership | ||
| Held by institutions | 87.1% | 56.7% |
| Held by insiders | 6.0% | 2.5% |
| Insider net buying, 12 months | −$986K (better) | −$2.9M |
| Short interest, % of float | 20.9% | 8.4% |
Go deeper
- EBS stock overview
- EBS income statement
- EBS valuation and score
- MNKD stock overview
- MNKD income statement
- MNKD valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.